Table IV.

Subjects stratified by treatment-specific¹ baseline C-peptide levels in the three insulin treatment groups of type 2 diabetic patients at baseline and at 12 month follow-up visit.

		Fasting glucose				HbA1c				Body weight
	n	Baseline	12 months	change	CI	Baseline	12 months	Change	CI	Baseline	12 months	change	CI
Low C-peptide
Insulin only	5	13.5	11.2	−3.3	−10.9,4.4	9.1	8.5	−0.9	−2.6,0.9	82.9	91.6	5.9	−0.1,11.9
Glipizide + insulin	9	12.9	8.6	−3.7	−7.7,0.4	9.9	8.4	−1.5	−2.3,−0.8	83.0	87.8	5.4	1.4,9.4
Metformin + Insulin	17	12.4	7.9	−4.1	−5.9,−2.3	9.9	8.6	−1.4	−1.9,−0.8	81.6	85.0	3.4	1.3,5.4
All patients	31	12.6	8.3	−4.5	−5.4,−2.3	9.8	8.5	−1.3	−1.7,−0.9	82.1	86.4	3.9	2.7,6.0
High C-peptide
Insulin only	5	13.2	9.9	−4.7	−13.5,4.0	10.2	7.0	−2.8	−4.8,−0.8	86.4	93.5	6.7	0.4,13.0
Glipizide + insulin	6	11.7	10.4	−1.9	−6.9,3.0	9.4	9.0	−0.8	−1.8,1.7	93.6	98.3	3.7	2.1,5.3
Metformin + insulin	7	12.5	7.4	−4.8	−7.6,−1.9	10.3	8.1	−1.7	−2.9,−0.5	81.9	86.5	3.5	−0.3,7.3
All patients	18	12.3	9.2	−3.1	−6.1,−1.3	9.9	8.3	−1.4	−2.4,−0.5	87.3	93.1	5.2	2.6,6.4

¹Stratification by median value: insulin only; low C-peptide <1.8 nmol/l, INS + GLI and INS + MET, low C-peptide <1.3 nmol/l. The number of patients may vary slightly at different time points.